Why Eliquis®? | Eliquis® | PfizerPro India

This site is intended only for healthcare professionals resident in India

Log Out

Our medicines

Therapy areas

Explore Content

Explore content

Events

Materials

Videos

Let's connect

Pfizer medical information

OnConnect

Dosage & Switch

SPAF Dosing

VTE Dosing

Efficacy & Safety

RCT Data: Efficacy and Safety in SPAF

RCT Data: Efficacy and Safety in VTE

RCT Data: Efficacy and Safety in SPAF

Eliquis® in a Broad Range of Patients With NVAF

Apixaban & Other NOACs

Support & Services

Summary of Prescribing Information

Expert Webinars

Why Eliquis^®?

*No head-to-head trials between the NOACs have been conducted.

^†Accounting for more patient treatment days prescribed^‡ around the world than any other OAC within NVAF & VTE indications.^§
^‡Patient treatment days prescribed estimated based on the latest six-month period, IQVIA MIDAS Q3'21 Sell-In/Sell-Out data. Standard Units divided by recommended administration of each DOAC within 24 hours. [apixaban BID, dabigatran BID, edoxaban QD, rivaroxaban QD].
VKA drugs treatment days estimated based on standard units divided by IQVIA MIDAS Medical average daily dose.
^§Indications accounted for by factoring standard unit volume based on IQVIA medical audit data and relevant WHO ICD10 codes.

AF, atrial fibrillation; NOAC, non-vitamin K antagonist oral anticoagulant; SE, systemic embolism.

References:

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.

Hur M, Park SK, Koo CH, et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. Acta Orthop. 2017;88(6):634-641.

Cohen AT, Imfeld S, Rider T. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther. 2014;31(5):473-493.

Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients [published correction appears in Stroke. 2020 Feb;51(2):e44] [published correction appears in Stroke. 2020 Apr;51(4):e71]. Stroke. 2018;49(12):2933-2944.

Eliquis. Local product document. Pfizer; 2022. LPDELI062022. Version 16.

Hanna MS, Mohan P, Knabb R, Gupta E, Frost C, Lawrence JH. Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Ann N Y Acad Sci. 2014;1329(1):93-106.

Data on file IQVIA MIDAS Q3’21 Sell-In/Sell-Out data.

Drazens Dozen. May 2019. Available on https://cdn.nejm.org/pdf/Drazens-Dozen.pdf Accessed on 14th April 2022.

Disclaimer: The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.

Please click the Prescribing Information link to view the safety and adverse events information of Eliquis®.
For the use only of Registered Medical Practitioners, or a hospital or a laboratory.

PP-ELI-IND-1567 25 July 2022

About

Contact Center for Health Care Professionals | Monday to Saturday 9:00 AM to 6:00 PM IST(exlcuding public holidays)

0008000503188

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.

Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.

PP-ELI-IND-1567

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Button

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein

You are now leaving PfizerPro website

You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-DOL-IND-0597 01 Mar 2024